Back
64
Also listed as
NONOF
OTC
Day Range
$36.35
$37.21
52-Week Range
$35.85
$81.44
Volume
14,976,721
50D / 200D Avg
$48.31
/
$54.90
Prev Close
$36.53
Price History
Financial Trends
Peer Comparison
vs Healthcare sector median (626 peers)
| Metric | Stock | Sector Median |
|---|---|---|
| P/E | 1.7 | 0.4 |
| P/B | 0.8 | 2.9 |
| ROE % | 58.4 | 3.7 |
| Net Margin % | 33.1 | 3.8 |
| Rev Growth 5Y % | 20.5 | 10.0 |
| D/E | 0.7 | 0.2 |
Key Takeaways
Revenue grew 20.53% annually over 5 years — strong growth
ROE of 58.36% indicates high profitability
Net margin of 33.14% shows strong profitability
Generating 28.99B in free cash flow
P/E of 1.66 — trading at a low valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 18.19%
Growth
Revenue Growth (5Y)
20.53%
Revenue (1Y)2.34%
Earnings (1Y)-2.46%
FCF Growth (3Y)-35.65%
Quality
Return on Equity
58.36%
ROIC29.96%
Net Margin33.14%
Op. Margin43.69%
Safety
Debt / Equity
0.67
Current Ratio0.80
Interest Coverage19.92
Valuation
P/E Ratio
1.66
P/B Ratio0.84
EV/EBITDA2.07
Dividend Yield0.03%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 2.34% | Revenue Growth (3Y) | 13.12% |
| Earnings Growth (1Y) | -2.46% | Earnings Growth (3Y) | 8.49% |
| Revenue Growth (5Y) | 20.53% | Earnings Growth (5Y) | 19.84% |
| Profitability | |||
| Revenue (TTM) | 297.20B | Net Income (TTM) | 98.50B |
| ROE | 58.36% | ROA | 18.14% |
| Gross Margin | 80.34% | Operating Margin | 43.69% |
| Net Margin | 33.14% | Free Cash Flow (TTM) | 28.99B |
| ROIC | 29.96% | FCF Growth (3Y) | -35.65% |
| Safety | |||
| Debt / Equity | 0.67 | Current Ratio | 0.80 |
| Interest Coverage | 19.92 | Dividend Yield | 0.03% |
| Valuation | |||
| P/E Ratio | 1.66 | P/B Ratio | 0.84 |
| P/S Ratio | 0.55 | PEG Ratio | 8.49 |
| EV/EBITDA | 2.07 | Dividend Yield | 0.03% |
| Market Cap | 163.63B | Enterprise Value | 268.12B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 297.20B | 290.40B | 232.26B | 176.95B | 140.80B |
| Net Income | 98.50B | 100.99B | 83.68B | 55.53B | 47.76B |
| EPS (Diluted) | 23.03 | 22.63 | 18.62 | 12.22 | 10.37 |
| Gross Profit | 238.77B | 245.88B | 196.50B | 148.51B | 117.14B |
| Operating Income | 129.83B | 128.34B | 102.57B | 74.81B | 58.64B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 542.90B | 465.80B | 314.49B | 241.26B | 194.51B |
| Total Liabilities | 348.86B | 322.31B | 207.93B | 157.77B | 123.76B |
| Shareholders' Equity | 194.05B | 143.49B | 106.56B | 83.49B | 70.75B |
| Total Debt | 130.96B | 102.79B | 27.01B | 25.78B | 26.65B |
| Cash & Equivalents | 26.46B | 15.66B | 14.39B | 12.65B | 10.72B |
| Current Assets | 172.45B | 160.90B | 139.65B | 108.19B | 85.60B |
| Current Liabilities | 215.66B | 217.53B | 169.66B | 120.94B | 99.52B |
Strategy Scores
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
#73 of 658
Recent Activity
Entered
Contrarian Investing (David Dreman)
Mar 24, 2026